From Bench to Bedside: Transforming Cancer Therapy with Protease Inhibitors DOI Open Access
Alireza Shoari

Targets, Год журнала: 2025, Номер 3(1), С. 8 - 8

Опубликована: Март 3, 2025

Proteases play a pivotal role in cancer progression, facilitating processes such as extracellular matrix degradation, angiogenesis, and metastasis. Consequently, protease inhibitors have emerged promising therapeutic agents oncology. This review provides comprehensive overview of the mechanisms by which modulate biology, categorizing their target classes, including metalloproteinases, cysteine proteases, serine proteases. We discuss potential both synthetic natural inhibitors, highlighting applications preclinical clinical settings. Furthermore, challenges specificity, toxicity, resistance are addressed, alongside strategies to overcome these limitations through innovative drug designs combination therapies. The future treatment lies precision medicine, leveraging proteomic profiling tailor therapies individual tumors. underscores importance ongoing research development novel approaches harness effectively for management.

Язык: Английский

Recent Advancements in Gallic Acid-Based Drug Delivery: Applications, Clinical Trials, and Future Directions DOI Creative Commons
Ranjit K. Harwansh, Rohitas Deshmukh,

V Shukla

и другие.

Pharmaceutics, Год журнала: 2024, Номер 16(9), С. 1202 - 1202

Опубликована: Сен. 13, 2024

Gallic acid (GA) is a well-known herbal bioactive compound found in many herbs and foods like tea, wine, cashew nuts, hazelnuts, walnuts, plums, grapes, mangoes, blackberries, blueberries, strawberries. GA has been reported for several pharmacological activities, such as antioxidant, inflammatory, antineoplastic, antimicrobial, etc. Apart from its incredible therapeutic benefits, it associated with low permeability bioavailability issues, limiting their efficacy. belongs to BCS (Biopharmaceutics classification system) class III (high solubility probability). In this context, novel drug delivery approaches played vital role resolving these issues. Nanocarrier systems help improve moiety’s physical chemical stability by encapsulating them into lipidic or polymeric matrix core system. regard, researchers have developed wide range of nanocarrier GA, including liposomes, transfersomes, niosomes, dendrimers, phytosomes, micelles, nanoemulsions, metallic nanoparticles, solid lipid nanoparticles (SLNs), nanostructured carriers, polymer conjugates, the present review, different search engines Scopus, PubMed, ScienceDirect, Google Scholar referred acquiring recent information on theme work. Therefore, review paper aims emphasize systems, patents, clinical updates GA.

Язык: Английский

Процитировано

6

Paclitaxel prodrug nanoparticles boost antitumor efficacy via hitchhiking of human serum albumin DOI

Shaojin Lu,

Shiyu Zhou,

Xiujuan Xiang

и другие.

Journal of Colloid and Interface Science, Год журнала: 2024, Номер 679, С. 144 - 154

Опубликована: Окт. 16, 2024

Язык: Английский

Процитировано

4

Advancing Cancer Drug Delivery with Nanoparticles: Challenges and Prospects in Mathematical Modeling for In Vivo and In Vitro Systems DOI Open Access
Tozivepi Aaron Munyayi, Anine Crous

Cancers, Год журнала: 2025, Номер 17(2), С. 198 - 198

Опубликована: Янв. 9, 2025

Mathematical models are crucial for predicting the behavior of drug conjugate nanoparticles and optimizing delivery systems in cancer therapy. These simulate interactions among nanoparticle properties, tumor characteristics, physiological conditions, including resistance targeting specificity. However, they often rely on assumptions that may not accurately reflect vivo conditions. In vitro studies, while useful, fully capture complexities environment, leading to an overestimation nanoparticle-based therapy effectiveness. Advancements mathematical modeling, supported by preclinical data artificial intelligence, vital refining therapies improving their translation into effective clinical treatments.

Язык: Английский

Процитировано

0

Surface Functionalization of Nanocarriers with Anti-EGFR Ligands for Cancer Active Targeting DOI Creative Commons

Alessandra Spada,

Sandrine Gerber‐Lemaire

Nanomaterials, Год журнала: 2025, Номер 15(3), С. 158 - 158

Опубликована: Янв. 21, 2025

Active cancer targeting consists of the selective recognition overexpressed biomarkers on cell surfaces or within tumor microenvironment, enabled by ligands conjugated to drug carriers. Nanoparticle (NP)-based systems are highly relevant for such an approach due their large surface area which is amenable a variety chemical modifications. Over past decades, several studies have debated efficiency passive targeting, highlighting active as more specific and approach. The choice conjugation chemistry attaching nanocarriers critical ensure stable robust system. Among panel biomarkers, epidermal growth factor receptor (EGFR) stands one most frequently receptors in different types. design development with surface-bound anti-EGFR vital targeted therapy, relying facilitated capture EGFR-overexpressing cells enabling receptor-mediated endocytosis improve accumulation microenvironment. In this review, we examine examples recent significant explore various strategies NP functionalization biomolecules small molecular ligands. addition, also describe some common characterization techniques confirm analyze patterns.

Язык: Английский

Процитировано

0

Nanostructured Formulations for a Local Treatment of Cancer: A Mini Review About Challenges and Possibilities DOI Creative Commons
Tatiane Roquete Amparo, Tamires Cunha Almeida, Lucas Resende Dutra Sousa

и другие.

Pharmaceutics, Год журнала: 2025, Номер 17(2), С. 205 - 205

Опубликована: Фев. 6, 2025

Cancer represents a significant societal, public health, and economic challenge. Conventional chemotherapy is based on systemic administration; however, it has current limitations, including poor bioavailability, high-dose requirements, adverse side effects, low therapeutic indices, the development of multiple drug resistance. These factors underscore need for innovative strategies to enhance delivery directly tumours. However, local treatment also presents challenges, penetration through endothelial layers, tissue density in tumour microenvironment, interstitial fluid pressure, physiological conditions within tumour, permanence at site action. Nanotechnology promising alternative addressing these challenges. This narrative review elucidates potential nanostructured formulations cancer treatment, providing illustrative examples an analysis advantages challenges associated with this approach. Among nanoformulations developed breast, bladder, colorectal, oral, melanoma cancer, polymeric nanoparticles, liposomes, lipid nanohydrogels have demonstrated particular efficacy. systems permit mucoadhesion enhanced penetration, thereby increasing concentration (bioavailability) consequently improving anti-tumour efficacy potentially reducing effects. In addition studies indicating chemotherapy, nanocarriers can be used as theranostic approach combination irradiation methods.

Язык: Английский

Процитировано

0

A computer-aided, carrier-free drug delivery system with enhanced cytotoxicity and biocompatibility: a universal model for multifunctional lung cancer therapy DOI
Zhonglei Wang,

Wenjing Xu,

Shizeng Lei

и другие.

Colloids and Surfaces B Biointerfaces, Год журнала: 2025, Номер 250, С. 114557 - 114557

Опубликована: Фев. 9, 2025

Язык: Английский

Процитировано

0

From Bench to Bedside: Transforming Cancer Therapy with Protease Inhibitors DOI Open Access
Alireza Shoari

Targets, Год журнала: 2025, Номер 3(1), С. 8 - 8

Опубликована: Март 3, 2025

Proteases play a pivotal role in cancer progression, facilitating processes such as extracellular matrix degradation, angiogenesis, and metastasis. Consequently, protease inhibitors have emerged promising therapeutic agents oncology. This review provides comprehensive overview of the mechanisms by which modulate biology, categorizing their target classes, including metalloproteinases, cysteine proteases, serine proteases. We discuss potential both synthetic natural inhibitors, highlighting applications preclinical clinical settings. Furthermore, challenges specificity, toxicity, resistance are addressed, alongside strategies to overcome these limitations through innovative drug designs combination therapies. The future treatment lies precision medicine, leveraging proteomic profiling tailor therapies individual tumors. underscores importance ongoing research development novel approaches harness effectively for management.

Язык: Английский

Процитировано

0